Healthcare provider profile · identity verified

Henry Lam Tran

Family Practice · POMONA, CA · NPI 1295197473

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	264	120
Rosuvastatin Calcium	Rosuvastatin Calcium	207	87
Lisinopril	Lisinopril	204	86
Losartan Potassium	Losartan Potassium	172	70
Levothyroxine Sodium	Levothyroxine Sodium	158	59
Amlodipine Besylate	Amlodipine Besylate	156	70
Omeprazole	Omeprazole	114	44
Pantoprazole Sodium	Pantoprazole Sodium	103	45
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	98	54
Metformin Hcl	Metformin Hcl	92	39
Albuterol Sulfate Hfa	Albuterol Sulfate	90	52
Glipizide	Glipizide	78	33
Metformin Hcl Er	Metformin Hcl	77	35
Gabapentin	Gabapentin	73	31
Alendronate Sodium	Alendronate Sodium	70	31
Azelastine Hcl	Azelastine Hcl	67	37
Tamsulosin Hcl	Tamsulosin Hcl	67	29
Lidocaine	Lidocaine	66	22
Potassium Chloride	Potassium Chloride	61	29
Atenolol	Atenolol	60	25
Simvastatin	Simvastatin	54	23
Ozempic	Semaglutide	52	11
Metoprolol Tartrate	Metoprolol Tartrate	51	17
Jardiance	Empagliflozin	50	18
Trazodone Hcl	Trazodone Hcl	43	18
Clopidogrel	Clopidogrel Bisulfate	41	20
Sertraline Hcl	Sertraline Hcl	40	13
Allopurinol	Allopurinol	38	14
Pradaxa	Dabigatran Etexilate Mesylate	36	suppressed
Metoprolol Succinate	Metoprolol Succinate	35	18
Terazosin Hcl	Terazosin Hcl	34	12
Tramadol Hcl	Tramadol Hcl	34	13
Meloxicam	Meloxicam	33	19
Hydrochlorothiazide	Hydrochlorothiazide	32	17
Spiriva Respimat	Tiotropium Bromide	31	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	29	suppressed
Furosemide	Furosemide	29	17
Wixela Inhub	Fluticasone Propion/Salmeterol	27	11
Humulin N	Insulin Nph Human Isophane	26	12
Ibuprofen	Ibuprofen	26	18
Fenofibrate	Fenofibrate	25	11
Trospium Chloride	Trospium Chloride	25	suppressed
Finasteride	Finasteride	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	14
Famotidine	Famotidine	22	suppressed
Carvedilol	Carvedilol	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Azithromycin	Azithromycin	19	18
Alvesco	Ciclesonide	18	11
Ciclopirox	Ciclopirox	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	11
Topiramate	Topiramate	18	suppressed
Alprazolam	Alprazolam	17	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	17	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Amoxicillin	Amoxicillin	16	13
Baclofen	Baclofen	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Betamethasone Valerate	Betamethasone Valerate	14	suppressed
Lactulose	Lactulose	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Estradiol	Estradiol	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Prednisone	Prednisone	12	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	11	11
Buspirone Hcl	Buspirone Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error